Quote · The Peter Attia Drive
#395 - Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer's disease risk, and the effects of lipid-lowering therapies on brain health | Tom Dayspring, M.D.
Where this was said
Statins and brain health: cognition and Alzheimer's disease risk
At 1:13:52 · chapter starts 1:09:00
Peter pivots to pharmacology, and Tom draws an immediate boundary: only statins among all ApoB-lowering drug classes can penetrate the blood-brain barrier. PCSK9 inhibitors, bile acid sequestrants, ezetimibe, and CETP inhibitors all work outside the brain. In steady state, even hydrophilic statins (like rosuvastatin) ultimately reach the brain, so the lipophilicity distinction matters less than commonly assumed for long-term therapy. Since Alzheimer's pathology involves excessive neuronal cholesterol, the hypothesis that statins might benefit the brain by moderately reducing brain cholesterol synthesis is logically coherent and is supported by the data: meta-analyses of statin trials show statins are either neutral or beneficial with respect to dementia outcomes — no study has shown harm [1] — Tom Dayspring "All statins — hydrophilic or lipophilic — reach the brain in steady state and can reduce cholesterol synthesis there. Meta-analyses show st…" 1:10:00 . But the flip side is real: cholesterol is also essential for brain function, and some patients develop brain fog on statins that promptly resolves on discontinuation. Tom proposes this is the over-suppression subgroup — individuals in whom the statin too aggressively reduces brain cholesterol synthesis. Monitoring plasma desmosterol could identify these patients before symptoms emerge, allowing dose adjustments. Similarly, statins have been shown to reduce plasma 24S-hydroxycholesterol, which Tom interprets as evidence of normalized neuronal cholesterol levels.
All statins — hydrophilic or lipophilic — reach the brain in steady state and can reduce cholesterol synthesis there. Meta-analyses show statins are either neutral or beneficial for dementia risk, but some patients develop brain fog, which may reflect over-suppression. Plasma desmosterol can help calibrate the dose.
Of all ApoB-lowering drug classes (statins, ezetimibe, PCSK9 inhibitors, bile acid sequestrants, CETP inhibitors), only statins can penetrate the blood-brain barrier and affect brain cholesterol synthesis.
